PAD - Prescribing Advisory Database
PLEASE NOTE : This is a development system.

For Surrey PAD, please go to https://surreyccg.res-systems.net/PAD.

You are here : Home > PAD Profile : Brodalumab (Psoriasis) - Psoriasis

PAD Profile : Brodalumab (Psoriasis) - Psoriasis

Keywords :
Biologic, NICE, immunosuppressant, interleukin (IL) 17RA inhibitor, DMARD, bDmard, Disease modulating, Dermatology,
Brand Names Include :
Kyntheum

Traffic Light Status

Status 1 of 2.

Status :
Red
Formulations :
  • Not Specified
Trust Alignment :
Primary Care
ASPH
RSFT
SASH
SABP
Links :
Comments :
No comments returned.
Documents :

Status 2 of 2.

Status :
Red
Formulations :
  • Not Specified
Trust Alignment :
Primary Care
ASPH
RSFT
SASH
SABP
Links :
Comments :
No comments returned.
Documents :

Guidelines

The following guidelines are available for this indication.

Other Drugs

Other Indications

No indications returned.

Additional Documents

Committee Recommendations

Date
Committee Name
Narrative
04 October 2023
Surrey Heartlands Integrated Care System Area Prescribing Committee (APC)

The Surrey Heartlands Integrated Care System Area Prescribing Committee has agreed the reviewed and updated high cost immunomodulator psoriasis treatment pathway.

02 December 2020
Surrey Heartlands Integrated Care System Area Prescribing Committee (APC)

The Surrey Heartlands ICS Area Prescribing Committee have agreed an update of the Psoriasis High Cost immunomodulator Drug Treatment Pathway. 

The pathway has been updated following guidance from the Regional Medicines Optimisation Committee in May 2020, in relation to the sequential use of biologic medicines. The agreed process and associated documentation is saved here https://surreyccg.res-systems.net/PAD/Search/DrugConditionProfile/6549

18 June 2018
Surrey & North West Sussex Area Prescribing Committee (formerly Prescribing Clinical Network)

The Prescribing Clinical Network recommends Brodalumab as a treatment option for moderate to severe plaque psoriasis in line with NICE TA511 (March 2018).

Brodalumab for this indication will be considered as RED on the traffic light status (treatment should be initiated and continued by specialist clinicians)

Brodalumab is a payment by results excluded drug and specialists will be required to notify commissioners of initiation and response to treatment using the tick box proformas available on the blueteq system.

Associated BNF Codes

13. Skin
13.05.03. Drugs affecting the immune response
This site uses its own and third party cookies to function properly and to improve performance, to maintain the session and to personalise user experience, as well as to obtain anonymous statistics about the use of the website. Visit our Privacy and Cookie Policy for more information on our data collection practices. By clicking 'Accept' you agree to our use of cookies for the purposes listed.
Learn More